Replimune jumps 85% after FDA opens up third dose for skin cancer therapy
Replimune Group shares rallied Friday afternoon. The company said it reached a deal with the U.S. Food and Drug Administration to resubmit RP1, its experimental advanced melanoma drug. Shares jumped $3.96, or roughly 85%, to $8.64 after hitting $9.05. The SPDR S&P Biotech ETF added about 0.8%.